Brugada syndrome is an inherited arrhythmogenic disorder leading to sudden death predominantly in the 3-4 decade. To date the only reliable treatment is the implantation of a cardioverter defibrillator; however, better criteria for risk stratification are needed, especially for asymptomatic subjects. Brugada syndrome genetic bases have been only partially understood, accounting for o30% of patients, and have been poorly correlated with prognosis, preventing inclusion of genetic data in current guidelines. We designed an observational study to identify genetic markers for risk stratification of Brugada patients by exploratory statistical analysis. The presence of genetic variants, identified by SCN5A gene analysis and genotyping of 73 candidate polymorphisms, was correlated with the occurrence of major arrhythmic events in a cohort of 92 Brugada patients by allelic association and survival analysis. In all, 18 mutations were identified in the SCN5A gene, including 5 novel, and statistical analysis indicated that mutation carriers had a significantly increased risk of major arrhythmic events (P ¼ 0.024). In addition, we established association of five polymorphisms with major arrhythmic events occurrence and consequently elaborated a pilot risk stratification algorithm by calculating a weighted genetic risk score, including the associated polymorphisms and the presence of SCN5A mutation as function of their odds ratio. This study correlates for the first time the presence of genetic variants with increased arrhythmic risk in Brugada patients, representing a first step towards the design of a new risk stratification model.
INTRODUCTION
Brugada syndrome (BrS) is a cardiac disorder with estimated prevalence of 1:5000 in western countries, characterized by electrical ventricular instability leading to sudden cardiac death (SCD) predominantly in the 3-4 decade, although cases of infant death have also been reported. 1 Diagnosis is based on the presence of type I ECG, characterized by right bundle branch block and ST elevation in right precordial leads. 2, 3 To date the only reliable treatment is defibrillator (ICD) implantation. 4 Current guidelines select higher risk patients based mainly on the presence of syncope and spontaneous ECG. 5 However, predisposition of BrS patients to develop ventricular arrhythmias still cannot be easily predicted and new criteria for prognostic risk stratification are needed, especially for asymptomatic subjects.
BrS is genetically heterogeneous, SCN5A gene mutations accounting for o25%. 6 Accordingly, the emerging concept of arrhythmia genomics supports the idea of a complex disorder, where the cosegregation of different mutations and common genetic variants can contribute to the clinical phenotype. 7 The aim of our study was to evaluate the contribution of candidate genetic variants to the predisposition to malignant arrhythmias in a cohort of BrS patients. We identified disease-modifying variants associated with arrhythmic phenotype and elaborated an innovative model of risk stratification based on these genetic markers.
MATERIALS AND METHODS Patients
The investigation conformed to principles outlined in the Declaration of Helsinki. Written informed consent for genetic analysis was obtained. In all, 92 consecutive Italian BrS patients were diagnosed based on the presence of type I ECG, either spontaneous (n ¼ 43) or induced by flecainide infusion (n ¼ 49). 8 Patients were subjected to personal and family history acquisition, evaluation of blood electrolytes, 24 h Holter-ECG, echocardiography and, whenever possible, cardiac magnetic resonance imaging to exclude the presence of other conditions associated with ST elevation. Electrophysiological study was performed when possible, including measurement of conduction intervals and programmed ventricular stimulation from the right ventricular apex with a maximum of three ventricular premature beats with three basic pacing cycles (600-500 and 400 ms); the shortest coupling interval of the premature beats was limited to 200 ms. A patient was considered inducible when a sustained ventricular arrhythmia (defined as one lasting 430 s or requiring intervention to terminate) was induced. Therapeutic options and ICD implantation were evaluated according to current guidelines 5 and clinical judgment. Patients were followed at least yearly by clinical assessment, ECG, echocardiography and ICD check. Documented ventricular tachycardia/fibrillation, SCD or appropriate ICD shock were defined as major arrhythmic events (MAE). All relevant clinical and genetic data were collected in an electronic database.
Genetic analysis
Mutation detection. Genomic DNA was extracted from peripheral blood with Maxwell16 (Promega, Milano, Italy) and SCN5A gene-coding exons, including adjacent intronic regions, were screened by PCR, DHPLC (Transgenomic, Glasgow, UK) and automated DNA sequencing (ABI 3730, Applied Biosystems, Monza, Italy). For primer sequences, see Supplementary Table S1 . Variants were described using the Human Genome Variation Society guidelines for nomenclature. 9 SCN5A reference sequence was NCBI NM_000335. Mutations placement was assigned using a combination of Swissprot (http:// ca.expasy.org/uniprot/) and studies of linear topologies for sodium channel pore-forming alpha subunit. 10 SNPs selection and analysis. Candidate single nucleotide polymorphisms (SNPs) were selected among those previously described as modulating ECG intervals [11] [12] [13] [14] [15] [16] [17] or predisposition to arrhythmic events. [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] In particular, most variants were located in genes encoding cardiac voltage-dependent channels (KCNQ1, KCNH2, SCN5A, KCNJ11, KCNE1, KCNE2, KCNJ2), structural proteins (ANK2, GJA5, PALLD), sympathetic system modulators (ADRB1, ADRB2, ADRB3), blood pressure regulators (NOS1AP, PAI-1), modulators of ionic flows (PLN, CERKL, SLCO3A1), transcription factors (BRUNOL4, LITAF), regulators of cell morphology (NRG3) and other genes known to be associated to ECG intervals modulation (MDR1, CASQ2, NDRG4, NUBPL, RNF207; Supplementary Table S2) .
SNP genotyping was performed with GenomeLab SNPstream platform (Beckman Coulter, Brea, CA, USA), based on 48-plex PCR reaction followed by single base extension and tag-driven hybridization. Two-color fluorescence was detected by SNPstream and intensity signals converted into genotypes. Primers for multiplex PCR were designed by Autoprimer software (www.autoprimer.com; Supplementary Table S3 ). Manufacturer protocols were followed for reaction conditions and data analysis.
Statistical analysis
Association analyses were performed using PLINK-v1.07 (http://pngu.mgh. harvard.edu/Bpurcell/plink/), 32 StataSE 11 (StataCorp LP, College Station, TX, USA) and SPSS version 13.0 software (SPSS, Bologna, Italy). Quality control criteria were applied for SNP exclusion (genotype call rate o0.9; minor allele frequency o0.01 and Hardy-Weinberg equilibrium P-value r0.001 in controls represented by non-MAE patients). Each SNP was tested for allelic association using w 2 -test and odds ratio and relative 95% confidence intervals were measured. Genotypic association analysis was performed testing several inheritance models (dominant, additive and recessive).
Kaplan-Meier curves were exploited for survival analysis, defining survival time as the interval between birth and occurrence of MAE or last follow-up information. Log-rank test was used to compare survival distribution across groups according to the presence/absence of SCN5A mutation and SNPs genotypes. An uncorrected P-value of 0.05 was considered as statistically significant as these analyses were considered as exploratory.
A weighted genetic risk score algorithm was calculated based on the presence of SCN5A mutations and selected SNPs by multiplying the number of risk alleles found to be significantly associated at either association or survival analysis by the weight of that SNP, representing the natural log of the OR of each allele, and then taking the sum across the included SNPs. 33 Mann-Whitney test was used for weighted genetic risk score comparisons. The contribution of weighted genetic risk score to MAE prediction was evaluated generating a receiver operating characteristic curve by plotting the sensitivity of continuous weighted genetic risk score against 1 Àspecificity and calculating the area under the curve as measure of performance.
RESULTS

Patients clinical profile
Ninety-two consecutive Italian BrS patients (age 47.5 ± 13.7, 85.8% males) were considered (Table 1) . In all, 40 were symptomatic for cardiac arrest, ventricular tachycardia/fibrillation or syncope, while in 52 asymptomatic patients diagnosis of BrS was suspected during routine cardiac ECG or family screening. Twenty-nine patients showed family history for SCD and/or BrS ECG and 13 first-degree relatives suffered from SCD. Twenty-seven patients had supraventricular arrhythmias and 17 documented nonsustained ventricular tachycardia. Also, 46/82 tested patients resulted positive to electrophysiological study and 62 received ICD (Table 1) . Mean follow-up was 26±16.7 months; 12 patients experienced lifetime MAE, with mean age at the event 42 ± 12.4 years ( Table 2 ).
SCN5A mutation analysis 18 SCN5A mutations were identified in 17 BrS patients, as one carried two different variants (p.E1087PfsX57 and p.F1293S). All the mutations were private and included 15 missense substitutions, 1 nonsense mutation, 1 frameshift deletion and 1 insertion. Five variants had not been previously described ( Figure 1 , Table 3 ). Pathogenicity of these unreported variants was assessed by evaluating their absence in at least 200 control Italian chromosomes, in 1000 genomes (http://browser. 1000genomes.org) and Exome Sequencing Project (http://evs.gs. washington.edu/EVS/) databases and analyzing intra-familiar segregation. In addition, all the new variants were classified as potentially damaging protein function by in silico prediction softwares Polyphen 2 (http://genetics.bwh.harvard.edu/pph2/) and SIFT (http:// sift.jcvi.org/).
SCN5A mutations were distributed along the entire predicted topology of the Nav1.5 protein: one in N-terminus and one in C-terminus, three in transmembrane spanning segments, nine in intracellular and four in extracellular loops ( Figure 1 ). The functional effect of three of these mutations (p.S216L, p.E1087PfsX57, p.F1293S) on biophysics properties of the sodium channel Nav 1.5 has been previously evaluated and reported by our group. 34, 35 Kaplan-Meier curves were drawn considering lifetime occurrence of MAE as endpoint, demonstrating that SCN5A mutation carriers had an increased risk of MAE compared with non-carriers (P ¼ 0.024; Figure 2a ). Table 4) . Kaplan-Meier curves were subsequently drawn considering lifetime MAE and plotted for each of the 35 SNPs, showing an association with the time to MAE in four SNPs by Log-rank test (KCNH2_rs3815459 A , P ¼ 0.0001; MDR1_rs1045642 T , P ¼ 0.001; ANK2_rs3733617 T , P ¼ 0.005; NRG3_rs4933824 T , P ¼ 0.014) and a trend for KCNH2_rs3807375 A (P ¼ 0.06). These risk alleles were associated with an increased susceptibility to develop life-threatening arrhythmic events (Figure 2b-f) .
In addition, the trend of Kaplan-Meier curves allowed us to infer on possible SNPs inheritance traits, suggesting a dominant mechanism for KCNH2_rs3807375 (the presence of a single copy of the risk allele A was sufficient to give the risk phenotype) and co-dominance for KCNH2_rs3815459 (the heterozygous genotype had an intermediate risk between the two homozygous). MDR1_rs1045642 was compatible with recessive inheritance as only the presence of two T risk alleles was associated with arrhythmic phenotype. No patient was homozygous for the risk allele in NRG3_rs4933824 and ANK2_rs3733617. There was no evidence of epistasis among these risk loci and between SNPs and the presence of mutations (not shown).
We finally calculated a weighted genetic risk score to evaluate the potential of a pilot risk stratification model. The weight of each risk allele and the presence of SCN5A mutation was calculated as function of its odds ratio obtained with w 2 -test 33 (Table 4 ). Using this model, patients experiencing MAE had mean genetic risk score ¼ 6.36 ± 2.5, while event-free patients ¼ 2.87±1.99 (Mann-Whitney P ¼ 1.5 Â 10 À5 ; Figure 3a) . To further examine weighted genetic risk score discriminatory power, we performed receiver operating characteristic curve analysis showing an area under the curve ¼ 0.873 (CI 95% 0.791-0.956, P ¼ 3.24 Â 10 À5 ; Figure 3b) . A weighted genetic risk score cutoff value Z4.06 was considered to classify MAE BrS patients (sensitivity: 91,67%; specificity: 77,50%; accuracy: 0,84585). Risk stratification according to weighted genetic risk score value was also represented by Kaplan-Meier curves (P ¼ 0.0001, Figure 3c) .
Correlation of weighted genetic risk score with MAE occurrence was validated on 37 independent BrS patients, consecutively enrolled after the 92 index patients (age 40.4 ± 13.9, 86.5% males, 35% SCN5A mutation carriers) and never experiencing MAE. Their weighted genetic risk score was 3.23±1.58, significantly different from that of MAE patients of the original cohort (Mann-Whitney Po0.0001) and not from non-MAE patients (Mann-Whitney P ¼ 0.172).
DISCUSSION
We propose for the first time a role of genetics in BrS risk stratification, correlating the presence of SCN5A gene mutations and common SNPs with increased arrhythmic risk. Indeed, in our cohort, SCN5A mutation carriers experienced significantly increased risk of lifetime MAE compared with non-carriers (Figure 2a) . Although still controversial, this observation agrees with recent studies suggesting association of SCN5A mutations with arrhythmic phenotypes. Probst et al 36 described conduction defects in SCN5A mutation carriers. Other studies observed association between severe phenotypes and inactivating SCN5A mutations compared with milder Genetics in Brugada syndrome risk stratification E Sommariva et al variants. 37, 38 Recent studies suggested that the presence of SCN5A mutation was a significant predictor of cardiac events 39 and could be associated with recurrence of ventricular fibrillation. 40 Genetic and clinical heterogeneity is relevant in BrS. Indeed, the classical concept of BrS as a mendelian disease has been recently modified according to the idea of arrhythmia genomics, suggesting that different variants may contribute to the phenotype and sodium channel defects may be one of the contributory causes and not necessarily the main. 7, 41 Inter-individual genetic differences may modulate excitation-contraction physiology, influencing arrhythmia susceptibility and may even explain differences in clinical phenotype presentation among distinct ethnicities. 42, 43 Ion channels carry out their function as part of multiproteic complexes, interacting with accessory subunits and regulatory proteins. Variants impairing function or expression of one of these proteins or influencing indirectly cardiac contraction, such as vagal tone or vascular pressure, may thus create clinically detectable phenotypical differences. 44 Hence, the identification of genetic variants modulating the phenotype in BrS patients may be useful for risk stratification.
In this pilot study, we evaluated whether we could establish an association between MAE occurrence and the presence of selected genetic variants. Candidate SNPs were chosen based on the idea that a change in proteins involved in the modulation of cardiac excitability and ECG phenotype may influence vulnerability to arrhythmias. This study considered all BrS probands in our cohort independently from the presence of SCN5A mutations, according to the concept that patients should have common pathogenetic mechanisms underlying ST segment elevation. 45 As we did not include relatives, our cohort reflects the heterogeneity of a population referring to an arrhythmology department for various reasons (cardiac arrest, syncope, asymptomatic ECG alterations, family history for SCD), and it is thus not enriched for asymptomatic individuals identified only by intra-familiar genetic screening.
Allelic association and Kaplan-Meier survival analyses identified five variants significantly associated with arrhythmic phenotype (Figure 2b-f) . These SNPs were located on different linkage disequilibrium blocks, as results from HapMap analysis, and correlated with arrhythmic risk in an independent way, even if at present we cannot predict whether the modulator effect is linked to the SNP itself or to other variants in the same linkage disequilibrium block. HERG potassium channel seems to be important for arrhythmia susceptibility in our cohort. Indeed, we identified two SNPs in KCNH2 gene associated with MAE occurrence: KCNH2_rs3815459 and KCNH2_rs3807375, previously involved in QT interval modulation. 13 The association of these SNPs with arrhythmic events therefore underlines the importance of the depolarization/repolarization balance in BrS arrhythmogenesis. ANK2_rs3733617 is located in the gene encoding the structural protein ankyrin B, linking integral membrane proteins to the underlying spectrin-actin cytoskeleton and required for targeting and stability of Na/Ca exchanger, Na/K ATPase and IP3 receptor in cardiomyocytes. Mutations in this gene cause defects in sodium and calcium regulation and have been associated with sinus node dysfunction, atrial fibrillation and long QT syndrome type 4. 46 NRG3_rs4933824 localizes in the gene encoding the cardiac growth factor neuregulin 3, important during cardiac development and morphogenesis and previously associated to a prolonged QT. 12, 28 The reason why we did not observe any homozygous individual for the risk allele in NRG3_rs4933824 and ANK2_rs3733617 may be ascribed to their low minor allele frequency (o5%). MDR1_rs1045642 lays in the MDR1-ABCB1 gene, belonging to the superfamily of ATP-binding cassette transporters and recently described as a marker of resident cardiac stem/progenitor cell subpopulations, thus governing cardiac remodeling and regeneration. 47 In order to elaborate a pilot model for risk stratification based on genetic data, we calculated a weighted genetic risk score for each patient, considering genetic variants associated with MAE (presence of SCN5A mutation and the five significant SNPs). This score, calculated by weighting each genetic variant based on the association effect size (OR) with MAE (Table 4) , was significantly higher in MAE vs event-free patients (Figure 3) . These results support the emerging 'Multi-Hit Hypothesis' , suggesting that particular combinations of common genetic variations in biologically relevant genes can affect electrogenesis and propagation and therefore modulate arrhythmogenic risk. 48, 49 This concept has also been proposed in a recent work studying genetic complexity in sporadic idiopathic epilepsy, suggesting that oligogenic electrical relationship may likely have a role even in 'monogenic' channelopathies, as carriers of such mutations often show a spectrum of clinical phenotypes, including the absence of disease, even within the same pedigree. 50 Indeed, in our cohort 5 out of 7 individuals carrying Z3 risk genotypes had experienced MAE, while only 1 out of 29 patients not carrying any risk genotype suffered life-threatening arrhythmias. This observation corroborates the association between at-risk genotypes and severe phenotype and underline the possibility that the contemporary presence of these alleles may have a cumulative effect on the phenotype.
STUDY LIMITATIONS AND CONCLUSIONS
As the present study is based on data from a population of 92 patients, with 17 SCN5A mutation carriers and 12 MAE, statistical analysis may suffer from reduced power. Although discriminatory power of weighted genetic risk score was validated in 37 independent BrS patients, this model will need confirmation in larger cohorts. Moreover, other genetic variants may be involved in predisposition to MAE, prompting future genome-wide association genotyping or deep sequencing studies for their identification. Nevertheless, this study, for the first time, was able to correlate the presence of genetic variants with increased arrhythmic risk in BrS patients, representing a proof of principle that genetics can indeed have a role. Our data may thus constitute a first step towards the design of a new risk stratification model, which in the future might also be integrated with other variables associated with increased arrhythmic risk in BrS patients.
